Stifel Starts Alto Neuroscience (ANRO) at Buy, 'Novel Precision Psych Approach With Two Mid-Stage Shots on Goal'
Tweet Send to a Friend
Stifel analyst Paul Matteis initiates coverage on Alto Neuroscience (NYSE: ANRO) with a Buy rating and a price target of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
